Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06232122Recruiting
New PET scans to detect ovarian cancer recurrence
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
Taoyuan CityAges 30–80 - NCT06235437RecruitingPhase 1
Testing a new drug (ASD141) for advanced solid tumors
This early-phase trial tests a new drug called ASD141 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if it is safe and how well it works against the cancer.
TainanAges 18 years+ - NCT06235216RecruitingPhase 2
Sacituzumab govitecan for advanced thyroid cancer
This trial tests a new drug called sacituzumab govitecan for people with advanced thyroid cancer that has stopped responding to standard treatments. It may be an option for those with differentiated thyroid cancer (after certain prior therapies) or anaplastic thyroid cancer (first-line or after one prior treatment).
BarcelonaAges 18 years+ - NCT06236633Recruiting
Blocking an artery before rectal cancer surgery
This trial tests a technique called ischemic preconditioning, where doctors temporarily block a main artery in your gut before rectal cancer surgery to see if it helps reduce complications. If you are scheduled for this type of surgery and meet the health criteria, the study may offer more information about safer recovery.
MontpellierAges 18–90 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06240728RecruitingPhase 1
Testing NPX887 for advanced solid tumors with B7-H7 protein
This trial tests a new drug called NPX887 that targets a protein (B7-H7) on certain cancer cells to help your immune system fight them. It is for people with advanced solid tumors that have not responded to other treatments.
Baltimore, MarylandAges 18 years+ - NCT06242119Recruiting
Testing a new PET scanner prototype
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
KrakowAges 18 years+ - NCT06247449Recruiting
MRI screening for brain metastases in aggressive breast cancer
This trial uses an MRI scan to look for early signs of breast cancer spreading to the brain in people with certain aggressive breast cancer types (triple-negative or HER2-positive) that are stage IIb or III. The goal is to find and treat brain metastases earlier, before they cause symptoms.
Toronto, OntarioAges 18 years+ - NCT06248515RecruitingPhase 2
Sacituzumab govitecan for advanced thymic cancer
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06261814RecruitingPhase 2
Ultrasound to check chemoembolization for liver tumors
This trial uses a special ultrasound with a contrast agent to see how well a liver cancer treatment called TACE is working. It may help doctors better understand if the treatment is shrinking the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06263088Recruiting
Equity in GI Cancer Care Study
This trial is looking for Black patients newly diagnosed with any stage of gastrointestinal cancer to help improve cancer care and make sure research includes everyone. By joining, you help doctors learn how to better support patients like you.
Cleveland, OhioAges 18 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT06272240Recruiting
Tumor environment study in advanced ovarian cancer
This study looks at the environment around ovarian cancer tumors to better understand the disease. It might help researchers find new ways to treat patients with advanced ovarian cancer.
Udine, UDAges 18–80 - NCT06273176Recruiting
Surgery with or without brain mapping for recurrent glioblastoma
This study is testing whether using a special brain-mapping technique during surgery helps people with recurrent glioblastoma. It compares standard surgery to surgery with mapping to see if it leads to better outcomes for tumors near important brain areas.
San Francisco, CaliforniaAges Up to 90 years - NCT06274515RecruitingPhase 4
Study of resistance to breast cancer therapies
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
AnderlechtAges 18 years+ - NCT06276309Recruiting
Protein study of cervical neuroendocrine tumors
This study looks at the proteins in cervical neuroendocrine tumors to understand how they behave and how they affect long-term outcomes. It aims to find new markers that could help predict prognosis and guide treatment.
Fuzhou, FujianAges Any age - NCT06278506Recruiting
Comparing surgery versus ablation for small kidney tumors
This trial compares two standard treatments for small kidney tumors: removing the tumor surgically (resection) or destroying it with heat or cold (ablation). The goal is to see which approach works better for tumors 3 cm or smaller.
StockholmAges 18–99 - NCT06289517Recruiting
PET scan for cancers with high HER2 levels
This study is testing a new type of PET scan that uses a special molecule (68Ga-Her2-affibody) to find tumors that have high levels of HER2. It may help doctors better see where your cancer is and decide on the best treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06292897Recruiting
Obesity and prostate cancer tissue study
This study looks at how obesity might affect prostate cancer growth. It uses tissue samples to understand the role of certain metabolites in the tumor, which could lead to better treatments.
MilanAges 18 years+ - NCT06299202Recruiting
Predicting breast cancer treatment response with special mammogram
This study uses a special type of mammogram with contrast dye to see if it can predict how well breast cancer responds to chemotherapy before surgery. It's for people with HER2-positive or triple-negative breast cancer.
LyonAges 35 years+ - NCT06299891RecruitingPhase 2
Study of weight loss medication for youth with hypothalamic obesity
This study tests a combination of two medications, phentermine and topiramate, to see if they help young people with hypothalamic obesity lose weight safely. Hypothalamic obesity is rapid weight gain caused by injury to the hypothalamus, often from a brain tumor or its treatment.
Philadelphia, PennsylvaniaAges 6–28 - NCT06302465Recruiting
Narlumosbartmab plus chemo for bone cancers with giant cells
This trial tests a new drug called Narlumosbartmab added to standard chemotherapy for certain types of bone cancer that have eaten away at the bone and contain large, abnormal cells. It is for people who have not yet started standard treatment and whose tumors can be removed with surgery.
Beijing, Beijing MunicipalityAges 8 years+ - NCT06305910RecruitingPhase 1
Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Minneapolis, MinnesotaAges 2–25
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.